The three names you'll see most often in 2026 are Ozempic, Mounjaro and Wegovy. They're all GLP-1 receptor agonists. They all reliably cause weight loss. They're not interchangeable. Here's how endocrinologists actually pick.

What they share

All three:

  • Are once-weekly subcutaneous injections (with a pre-filled pen).
  • Mimic the gut hormone GLP-1: lower appetite, slow gastric emptying, improve insulin sensitivity.
  • Need refrigeration when not in use; have a 28-day room-temperature window once started.
  • Cause similar early side effects: nausea (most common), constipation, mild fatigue.

The differences are in what they bind to, which dose you reach, and what label they were approved under.

Ozempic — semaglutide for diabetes (approved 2017)

Maximum dose: 2.0 mg per week. It was first approved for type 2 diabetes; the weight loss was the “side effect” that turned out to matter enormously.

Weight loss
~10–14%
Average body-weight reduction at 1.0–2.0 mg over 12 months in real-world cohorts.

When we prescribe it: patients who have type 2 diabetes or pre-diabetes along with obesity. The cardiovascular and renal safety signals are excellent. Cost-effective; widely available.

Wegovy — semaglutide for weight (approved 2021)

Same molecule as Ozempic, but with a higher maximum dose (2.4 mg/week) and an approval specifically for chronic weight management in obesity or in overweight with comorbidity.

Weight loss
~14.9%
STEP-1 trial: average over 68 weeks, in adults with BMI ≥ 30.

When we prescribe it: patients without diabetes whose primary goal is weight reduction. Pricier than Ozempic in India, but the higher dose gives a bigger weight effect on average.

Mounjaro — tirzepatide (dual GLP-1 + GIP, approved 2022)

The newest of the three and structurally different: it activates GLP-1 and a second hormone receptor, GIP. The dual mechanism appears to push weight loss further than semaglutide alone.

Weight loss
~20.9%
SURMOUNT-1 trial: average at 15 mg over 72 weeks, in adults with obesity.

When we prescribe it: patients with higher starting BMI (often >35), strong commitment to a 12-month course, and budget for a slightly higher monthly cost. Also our first choice for patients with severe insulin resistance.

How we actually pick (a clinician's decision tree)

Roughly, the decision tree your ZIVOLABS doctor walks through:

  1. Do you have type 2 diabetes or pre-diabetes? Often start with Ozempic for the dual benefit.
  2. BMI > 35 or pronounced abdominal obesity? Mounjaro typically gives more total weight loss.
  3. Sensitive to nausea / history of GI issues? Slow titration on semaglutide (Ozempic / Wegovy) is often better tolerated.
  4. Strict budget? Ozempic at lower doses is the cheapest entry point.
  5. Need an oral option? Rybelsus (oral semaglutide) exists; lower weight effect but no needle.

What about Rybelsus (the tablet)?

Rybelsus is oral semaglutide. It's a real option for people who genuinely can't inject, but it has trade-offs:

  • Daily dosing (vs weekly).
  • Must be taken on an empty stomach, 30 minutes before food.
  • Lower bioavailability — weight loss is typically less than injectable semaglutide at equivalent doses.

For most patients, the once-weekly injection is more convenient and more effective. But the tablet is a perfectly legitimate option when injection isn't.

Switching between them

Switching is normal mid-course. If Ozempic isn't getting you to your weight goal at 2.0 mg, your doctor may suggest moving to Mounjaro for a few months. If Mounjaro is causing more GI side effects than you can tolerate, dropping to Wegovy at a lower dose is reasonable.

What matters: every switch should go through a doctor who's seen your check-ins, not a website that sells you whichever box you click. Real prescribing is a conversation about yourresponse, not a price comparison.